Rituximab in diffuse cutaneous systemic sclerosis: Should we be using it today?

Rheumatology (United Kingdom)

Volumn 54, Issue 5, 2014, Pages 757-767

  McQueen, Fiona M ^a,b   Solanki, Kamal ^c,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b GREEN LANE HOSPITAL   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

B cell depletion; Diffuse cutaneous systemic sclerosis; Rituximab

Indexed keywords

AUTOANTIBODY; RITUXIMAB;

ANIMAL MODEL; B LYMPHOCYTE; CASE CONTROL STUDY; CHRONIC GRAFT VERSUS HOST DISEASE; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMORAL IMMUNE DEFICIENCY; LUNG FIBROSIS; NONHUMAN; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; SCLERODERMA; SCLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE; SKIN FIBROSIS; SKINFOLD; SYSTEMIC SCLEROSIS;

EID: 84929663288     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu463     Document Type: Review

References (68)

1. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13(Suppl 1):S5.
2. Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
3. Jordan S, Distler JHW, Maurer B et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014, Advance Access published 17 January 2014, doi: 10.1136/annrheumdis-2013-204522.
4. Minier T, Guiducci S, Bellando-Randone S. Preliminary analysis of Very Early diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence of puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:2087-93.
5. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65:2737-47.
6. Daoussis D, Liossis S-NC, Tsamandas AC et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010;49:271-80.
7. Daoussis D, Liossis S-NC, Tsamandas AC et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30(2 Suppl 71):S17-22.
8. Bosello S, De Santis M, Lama G et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12:R54.
9. Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-83.
10. Smith V, Van Praet JT, Vandooren B et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69:193-7.
11. Smith V, Piette Y, van Praet JT et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013;40:52-7.
12. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-8.
13. Fleischmajer R, Perlish JS, West WP. Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 1977;113:1661-6.
14. Denton CP, Merkel PA, Furst DE et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
15. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
16. Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev 2013;22:236-43.
17. Keir GJ, Maher TM, Ming D et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9.
18. Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology 2014;53:975-87.
19. Huyan X-H, Lin Y-P, Gao T, Chen R-Y, Fan Y-M. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. Int Immunopharmacol 2011;11:1293-7.
20. Langford CA. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol 2011;164(Suppl 1):31-4.
21. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
22. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
23. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976;82:493-512.
24. Jimenez SA, Williams CJ, Myers JC, Bashey RI. Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem 1986;261:657-62.
25. Siracusa LD, McGrath R, Ma Q et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996;6:300-13.
26. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-66.
27. Komura K, Yanaba K, Horikawa M et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008;58:3574-84.
28. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004;41:1123-33.
29. Yoshizaki A, Iwata Y, Komura K et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172:1650-63.
30. Kim JB, Liakopoulou E, Watson JS. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease. J Plast Reconstr Aesthet Surg 2008;61:1235-8.
31. Cutler C, Miklos D, Kim HT et al. Rituximab for steroidrefractory chronic graft-versus-host disease. Blood 2006; 108:756-62.
32. Dignan FL, Amrolia P, Clark A et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012;158:46-61.
33. Whitfield ML, Finlay DR, Murray JI et al. Systemic and cell type_specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24.
34. Riemekasten G, Philippe A, Nather M et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011;70:530-6.
35. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
36. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-48.
37. Tan FK, Arnett FC, Reveille JD et al. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000;43:2464-71.
38. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25:296-301.
39. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
40. Nikpour M, Hissaria P, Byron J et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13:R211.
41. Chung L, Utz PJ. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 2004;6:156-63.
42. Francois A, Chatelus E, Wachsmann D et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013;15:R168.
43. Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis-a lethal component of systemic sclerosis. Nat Rev Rheumatol 2014;10:390-402.
44. Hinz B, Dugina V, Ballestrem C, Wehrle-Haller B, Chaponnier C. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol Biol Cell 2003;14:2508-19.
45. Daoussis D, Tsamandas AC, Liossis S-NC et al. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 2012;14:R145.
46. Sumida H, Asano Y, Tamaki Z et al. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 2014;41:418-20.
47. Dalbeth N, Smith T, Gray S et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis 2009;68:279-82.
48. Humby F, Bombardieri M, Manzo A et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6:e1.
49. Lopez De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009;60:1160-72.
50. Yousem SA, Schneider F, Bi D et al. The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Hum Pathol 2014;45:1199-204.
51. Hansen A, Lipsky PE, Dorner T. B cells in Sjögren's syndrome:indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007;9:218.
52. Shiboski SC, Shiboski CH, Criswell LA et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012;64:475-87.
53. McQueen F, Elliott B. B cell lymphoproliferation and organ-directed self-recognition to explain autoimmunity:back to the past. Med Hypotheses 2010;75:328-33.
54. Doorenspleet ME, Klarenbeek PL, de Hair MJH et al. Rheumatoid arthritis synovial tissue harbours dominant Bcell and plasma-cell clones associated with autoreactivity. Ann Rheum Dis 2014;73:756-62.
55. Scheel T, Gursche A, Zacher J, Haupl T, Berek C. V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum 2011;63:63-72.
56. Lindop R, Arentz G, Chataway TK et al. Molecular signature of a public clonotypic autoantibody in primary Sjögren's syndrome: a ''forbidden'' clone in systemic autoimmunity. Arthritis Rheum 2011;63:3477-86.
57. Keystone E, Emery P, Peterfy CG et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009; 68:216-21.
58. Carubbi F, Cipriani P, Marrelli A et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome:a prospective, multi-center, follow-up study. Arthritis Res Ther 2013;15:R172.
59. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71.
60. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus:a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
61. Merrill J, Buyon J, Furie R et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709-16.
62. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus:results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458-66.
63. Moroni G, Raffiotta F, Trezzi B. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014;53:1570-7.
64. Wardemann H, Yurasov S, Schaefer A et al. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-7.
65. van Vollenhoven RF, Emery P, Bingham CO III et al. Long-term safety of rituximab in rheumatoid arthritis:9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
66. Clifford DB, Ances B, Costello C et al. Rituximabassociated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
67. Itoh K, Kano T, Nagashio C et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:1020-2.
68. Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology 2008;47:224-5.